-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GfUGcRm4DbeAaplhGQWWOZPFsdRHiY7VtAaoQKkc8zb2qz8lhvpmfu0p7OOZJml2 f3df6qRM66vWI65KsDmscw== 0000950133-00-000552.txt : 20000216 0000950133-00-000552.hdr.sgml : 20000216 ACCESSION NUMBER: 0000950133-00-000552 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000215 GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH FOCUS S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOCHEM PHARMA INC CENTRAL INDEX KEY: 0000867202 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: E6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-45089 FILM NUMBER: 545065 BUSINESS ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD CITY: LAVAL QUEBEC STATE: E6 BUSINESS PHONE: 5146811744 MAIL ADDRESS: STREET 1: 275 ARMAND FRAPPIER BLVD CITY: LAVAL QUEBEC STATE: E6 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13G/A 1 AMENDMENT NO.1 TO SCHEDULE 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* BIOCHEM PHARMA, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, NO PAR VALUE PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 09058T108 ------------------- (CUSIP Number) - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed " for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 8 pages 2 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BB BIOTECH AG - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization SWITZERLAND - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- -0- ficially Owned by Each -------------------------------------------------------- Reporting Person With: 6. Shared Voting Power 1,027,500 -------------------------------------------------------- 7. Sole Dispositive Power -0- -------------------------------------------------------- 8. Shared Dispositive Power 1,027,500 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,027,500 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 0.94% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) HC, CO - -------------------------------------------------------------------------------- Page 2 of 8 pages 3 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH FOCUS S.A. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization PANAMA - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- -0- ficially -------------------------------------------------------- Owned by Each Reporting 6. Shared Voting Power Person With: 1,027,500 -------------------------------------------------------- 7. Sole Dispositive Power -0- -------------------------------------------------------- 8. Shared Dispositive Power 1,027,500 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned By Each Reporting Person 1,027,500 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 0.94% - -------------------------------------------------------------------------------- 12. Type of Reporting Person CO - -------------------------------------------------------------------------------- Page 3 of 8 pages 4 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- ITEM 1. (a) Name of Issuer Biochem Pharma, Inc. (b) Address of Issuer's Principal Executive Offices 275 Frappier Boulevard, Laval, Quebec, Canada H7V 4A7. ITEM 2. (a) Name of Person Filing BB Biotech AG ("BB Biotech") Biotech Focus S.A. ("Biotech Focus") (b) Address of Principal Business Office or, if none, Residence BB Biotech Biotech Focus Vordergasse 3 Swiss Bank Tower 8200 Schaffhausen Panama 1 CH/Switzerland Republic of Panama (c) Citizenship See Item No. 4 of cover pages. (d) Title of Class of Securities Common Stock, No Par Value Per Share (e) CUSIP Number 09058T108 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). Page 4 of 8 pages 5 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- (e) [ ] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,027,500 (b) Percent of class: 0.94% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote -0- (ii) Shared power to vote or to direct the vote 1,027,500 (iii) Sole power to dispose or to direct the disposition of -0- (iv) Shared power to dispose or to direct the disposition of 1,027,500 Page 5 of 8 pages 6 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY This statement is filed jointly by BB Biotech and Biotech Focus. Biotech Focus is a wholly-owned subsidiary of BB Biotech. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. ITEM 9. Not applicable. ITEM 10. CERTIFICATION By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 6 of 8 pages 7 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: February 14, 2000 By: /s/ N. FREY ---------------------- Name: N. Frey ----------------------- Date: February 14, 2000 By: /s/ D. RACNJAK ----------------------- Name: D. Racnjak ----------------------- ----------------------- BIOTECH FOCUS S.A. Date: February 14, 2000 By: /s/ N. FREY ----------------------- Name: N. Frey ----------------------- ----------------------- Date: February 14, 2000 By: /s/ D. RACNJAK ---------------------- Name: D. Racnjak ---------------------- ---------------------- Signatory Authority Page 7 of 8 pages 8 CUSIP No. 09058T108 - -------------------------------------------------------------------------------- EXHIBIT INDEX Exhibit 1: Agreement by and between BB Biotech and Biotech Focus with respect to the filing of this disclosure statement.* - --------------------- * Previously filed. Page 8 of 8 pages -----END PRIVACY-ENHANCED MESSAGE-----